The correlation between <i>CMTM2</i> methylation and prognosis of patients in hepatocellular carcinoma

XU Yuqiu; XU Yuge; GUO Xuefeng; LIU Guoyu; DU Yuanxiao; LYU Xiao; BEI Chunhua

doi:10.16462/j.cnki.zhjbkz.2023.06.013

Volume 27 Issue 6

Jun. 2023

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2023 > 27(6): 691-697

XU Yuqiu, XU Yuge, GUO Xuefeng, LIU Guoyu, DU Yuanxiao, LYU Xiao, BEI Chunhua. The correlation between CMTM2 methylation and prognosis of patients in hepatocellular carcinoma[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(6): 691-697. doi: 10.16462/j.cnki.zhjbkz.2023.06.013

Citation:

XU Yuqiu, XU Yuge, GUO Xuefeng, LIU Guoyu, DU Yuanxiao, LYU Xiao, BEI Chunhua. The correlation between CMTM2 methylation and prognosis of patients in hepatocellular carcinoma[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(6): 691-697. doi: 10.16462/j.cnki.zhjbkz.2023.06.013

Citation:

PDF( 9553 KB)

The correlation between CMTM2 methylation and prognosis of patients in hepatocellular carcinoma

doi: 10.16462/j.cnki.zhjbkz.2023.06.013

Department of Epidemiology and Biostatistics, School of Public Health, Guilin Medical University, Guangxi Key Laboratory of Environmental Exposomics and Entire Lifecycle Heath, Guilin 541199, China

Funds:

The National Natural Science Foundation of China 82260664

Natural Science Foundation of Guangxi Province 2020GXNSFAA297142

More Information

Corresponding author: BEI Chunhua, E-mail: chunhuabei@glmc.edu.cn
Received Date: 2022-09-15
Rev Recd Date: 2022-12-08

Available Online: 2023-07-10

Publish Date: 2023-06-10

Abstract

Abstract

Objective To determine the relationship between the methylation of the CMTM2 gene, its expression, and the prognosis of patients with hepatocellular carcinoma (HCC). Methods The CMTM2 methylation and gene expression data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. R software and Perl script were used to integrate the data. Correlation analysis was performed on the methylation and expression of CMTM2 in HCC and adjacent tissues. The differences in prognosis among HCC patients with varying levels of CMTM2 methylation were assessed. The Mass ARRAY nucleic acid mass spectrometry was used to detect the changes of CMTM2 methylation levels in HCC cells before and after treatment with DNA methylation inhibitors to verify the effect of DNA methylation on CMTM2 gene expression in vitro. Results Expression of the CMTM2 gene was found to be lower in HCC tissues than in adjacent tissues (P=0.007 5), and CMTM2 methylation was higher in HCC tissues than in adjacent tissues (P < 0.001). Kaplan-Meier survival analysis showed that patients with CMTM2 hypermethylation had shorter overall survival (HR=1.454 8, 95% CI: 1.022 3-2.070 5, P=0.037) and disease-free survival (HR=1.514 8, 95% CI: 1.095 3-2.094 8, P=0.012). The CMTM2 gene was hypermethylated at the cg07153665 site in the promoter region. Treatment with DNA methylation inhibitors significantly reduced the methylation level at the cg07153665 site, while the CMTM2 expression level was significantly upregulated. Conclusions Hypermethylation at the cg07153665 site affects the overall survival and disease-free survival of hepatocellular carcinoma patients by regulating the expression of CMTM2, suggesting that cg07153665 may be a potential prognostic assessment indicator and therapeutic target for hepatocellular carcinoma patients.
- CMTM2,
- Hepatocellular carcinoma,
- Prognosis,
- Methylation

FullText(HTML)

References(22)

References

[1]	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791. DOI: 10.1097/CM9.0000000000001474.
[2]	Han W, Ding P, Xu M, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation[J]. Genomics, 2003, 81(6): 609-617. DOI: 10.1016/s0888-7543(03)00095-8.
[3]	Shi S, Rui M, Han W, et al. CKLFSF₂ is highly expressed in testis and can be secreted into the seminiferous tubules[J]. Int J Biochem Cell Biol, 2005, 37(8): 1633-1640. DOI: 10.1016/j.biocel.2004.04.028.
[4]	Mays AC, Feng X, Browne JD, et al. Chemokine and chemokine receptor profiles in metastatic salivary adenoid cystic carcinoma[J]. Anticancer Res, 2016, 36(8): 4013-4018.
[5]	Choi JH, Kim YB, Ahn JM, et al. Identification of genomic aberrations associated with lymph node metastasis in diffuse-type gastric cancer[J]. Exp Mol Med, 2018, 50(4): 1-11. DOI: 10.1038/s12276-017-0009-6.
[6]	Guo X, Zhang S, Tan S, et al. Downregulated CMTM2 poses potential clinical significance in hepatocellular carcinoma[J]. DNA Cell Biol, 2020, 39(4): 683-689. DOI: 10.1089/dna.2019.5237.
[7]	Zhang S, Tian R, Bei C, et al. Down-regulated CMTM2 promotes epithelial-mesenchymal transition in hepatocellular carcinoma[J]. Onco Targets Ther, 2020, 13: 5731-5741. DOI: 10.2147/OTT.S250370.
[8]	Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps[J]. Nat Rev Genet, 2007, 8(4): 286-298. DOI: 10.1038/nrg2005.
[9]	Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond[J]. Nat Rev Genet, 2012, 13(7): 484-492. DOI: 10.1038/nrg3230.
[10]	Li M, Zhang C, Zhou L, et al. Identification and validation of novel DNA methylation markers for early diagnosis of lung adenocarcinoma[J]. Mol Oncol, 2020, 14(11): 2744-2758. DOI: 10.1002/1878-0261.12767.
[11]	Zheng H, Pomyen Y, Hernandez MO, et al. Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma[J]. Hepatology, 2018, 68(1): 127-140. DOI: 10.1002/hep.29778.
[12]	Losic B, Craig AJ, Villacorta-Martin C, et al. Intratumoral heterogeneity and clonal evolution in liver cancer[J]. Nat Commun, 2020, 11(1): 291. DOI: 10.1038/s41467-019-14050-z.
[13]	Fujihara Y, Oji A, Kojima-Kita K, et al. Co-expression of sperm membrane proteins CMTM2A and CMTM2B is essential for ADAM3 localization and male fertility in mice[J]. J Cell Sci, 2018, 131(19): jcs221481. DOI: 10.1242/jcs.221481.
[14]	Duan HJ, Li XY, Liu C, et al. Chemokine-like factor-like MARVEL transmembrane domain-containing family in autoimmune diseases[J]. Chin Med J (Engl), 2020, 133(8): 951-958. DOI: 10.1097/CM9.0000000000000747.
[15]	Wu J, Li L, Wu S, et al. CMTM family proteins 1-8: roles in cancer biological processes and potential clinical value[J]. Cancer Biol Med, 2020, 17(3): 528-542. DOI: 10.20892/j.issn.2095-3941.2020.0032.
[16]	Zhang XW, Yin HQ, Li Q, et al. CMTM2 is involved in spermiogenesis in mice[J]. Beijing Da Xue Xue Bao Yi Xue Ban, 2019, 51(2): 228-293. DOI: 10.19723/j.issn.1671-167X.2019.02.005.
[17]	Bogdanović O, Lister R. DNA methylation and the preservation of cell identity[J]. Curr Opin Genet Dev, 2017, 46: 9-14. DOI: 10.1016/j.gde.2017.06.007.
[18]	Duruisseaux M, Esteller M. Lung cancer epigenetics: From knowledge to applications[J]. Semin Cancer Biol, 2018, 51: 116-128. DOI: 10.1016/j.semcancer.2017.09.005.
[19]	Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers[J]. Gastroenterology, 2015, 149(5): 1204-1225. e12. DOI: 10.1053/j.gastro.2015.07.011.
[20]	Tahara T, Arisawa T. DNA methylation as a molecular biomarker in gastric cancer[J]. Epigenomics, 2015, 7(3): 475-486. DOI: 10.2217/epi.15.4.
[21]	Fang WJ, Zheng Y, Wu LM, et al. Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients[J]. Asian Pac J Cancer Prev, 2012, 13(5): 1917-1921. DOI: 10.7314/apjcp.2012.13.5.1917.
[22]	van Doorn R, Slieker RC, Boonk SE, et al. Epigenomic analysis of sezary syndrome defines patterns of aberrant DNA methylation and identifies diagnostic markers[J]. J Invest Dermatol, 2016, 136(9): 1876-1884. DOI: 10.1016/j.jid.2016.03.042.